In-Depth Adeno-Associated Virus Characterization with Microchip Capillary Electrophoresis-Mass Spectrometry

This webinar consists of two parts: Dr. Adi Kulkarni from 908 Devices begins by providing a brief introduction to the ZipChip CE-MS technology, highlighting its features and benefits. In part two, Dr. Josh Smith from NIBRT, demonstrates how microchip CE-MS can be applied to the characterization of AAVs, specifically VP characterization and peptide mapping.

This webinar consists of two parts: Dr. Adi Kulkarni begins by providing a brief introduction to the ZipChip CE-MS technology, highlighting its features and benefits, followed by Dr. Josh Smith from NIBRT, with a deep dive of the ZipChip CE-MS technology applied to the characterization of AAVs.

Commonly utilized liquid chromatography-mass spectrometry (LC-MS) characterization strategies are time consuming and sample intensive. Capillary electrophoresis (CE) is often adapted as an orthogonal alternative for biotherapeutic characterization because of its speed and sensitivity. However, the utility of CE is generally limited by poor compatibility with MS. ZipChip/MS overcomes these incompatibility issues enabling rapid in-depth characterization of biotherapeutics.

In the first part of the webinar, Dr. Kulkarni will provide an overview of the ZipChip/MS technology and explain the fundamental concepts behind how ZipChip/MS works. In the second part of the webinar, Dr. Smith will present results obtained by applying the ZipChip/MS to the characterization of Adeno-Associated Virus (AAV) capsid proteins. AAVs are viral vectors increasingly investigated for their clinical potential as delivery systems of gene therapy targets. Characterization of intact AAV capsids, their viral proteins (VPs), and their post-translational modifications (PTMs) is critical to monitoring and ensuring product quality and efficacy.  

Dr. Smith will demonstrate how microchip CE-MS can be applied to the characterization of AAVs, specifically VP characterization and peptide mapping. Performed across a spectrum of AAV serotypes, we discuss how this platform quickly provides crucial information related to the characteristics of AAVs including the presence of VP proteoforms and PTMs.

email Subscribe to Our Communications Signup to receive new product updates, technical tips and more.

Subscribe